Profound Medical Reports Preliminary Unaudited Q4 & FY23 Revenues
Ticker: PROF · Form: 6-K · Filed: Jan 3, 2024 · CIK: 1628808
| Field | Detail |
|---|---|
| Company | Profound Medical Corp. (PROF) |
| Form Type | 6-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: preliminary-results, revenue-update, medical-devices
TL;DR
**Profound Medical just dropped preliminary Q4 and FY2023 revenue numbers, giving us an early peek at their sales performance.**
AI Summary
Profound Medical Corp. announced preliminary unaudited revenues for Q4 and full year 2023 on January 3, 2024. While specific dollar amounts are not yet disclosed in this filing, the company, known for its incision-free medical devices, is providing an early look at its financial performance. This matters to investors because preliminary revenue figures can offer an early indication of the company's growth trajectory and market adoption of its TULSA-PRO and Sonalleve systems, influencing stock valuation before the full audited results are released.
Why It Matters
This filing gives investors an early, albeit unaudited, glimpse into Profound Medical's financial health and sales performance for the recent quarter and year, which can impact stock price and future expectations.
Risk Assessment
Risk Level: medium — The risk is medium because these are preliminary and unaudited figures, meaning they could change significantly when the final audited results are released, potentially surprising investors.
Analyst Insight
An investor should await the full audited financial results to get a complete picture of Profound Medical's performance, as preliminary figures are subject to change and lack detailed breakdowns. This filing serves as an alert to upcoming, more comprehensive data.
Key Players & Entities
- Profound Medical Corp. (company) — registrant and medical device company
- Rashed Dewan (person) — Chief Financial Officer of Profound Medical Corp.
- January 3, 2024 (date) — date of the press release and filing
- Q4 2023 (date) — period for which preliminary revenues are announced
- Full Year 2023 (date) — period for which preliminary revenues are announced
Forward-Looking Statements
- Profound Medical Corp. will release its full audited Q4 and full year 2023 financial results, including specific revenue figures, in a subsequent filing. (Profound Medical Corp.) — high confidence, target: Q1 2024
- The preliminary unaudited revenue figures will be generally consistent with the final audited figures, though minor adjustments are possible. (Profound Medical Corp.) — medium confidence, target: Q1 2024
FAQ
What is the purpose of this 6-K filing by Profound Medical Corp.?
The purpose of this 6-K filing is to report that Profound Medical Corp. has announced preliminary unaudited revenues for the fourth quarter and full year 2023, as detailed in the attached Exhibit 99.1, a press release dated January 3, 2024.
Who signed this 6-K filing on behalf of Profound Medical Corp.?
The 6-K filing was signed by Rashed Dewan, the Chief Financial Officer of Profound Medical Corp., on January 3, 2024.
What type of company is Profound Medical Corp.?
Profound Medical Corp. is described as a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, with a Standard Industrial Classification of SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841].
What specific financial information is included in this 6-K filing?
This 6-K filing includes an announcement of preliminary unaudited revenues for the fourth quarter and full year 2023, as stated in the attached press release (Exhibit 99.1). However, the actual dollar amounts for these revenues are not provided within the text of the 6-K itself, only the announcement that they have been made.
Under which SEC form does Profound Medical Corp. typically file its annual reports?
Profound Medical Corp. indicates by check mark that it files its annual reports under cover of Form 40-F, as shown in the filing.
Filing Stats: 165 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-01-03 17:00:10
Filing Documents
- f6k_010324.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-000042.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROFOUND MEDICAL CORP. (Registrant) Date: January 3, 2024 /s/ Rashed Dewan Rashed Dewan Chief Financial Officer